期刊文献+

多发性硬化患者血清TNF-α、IFN-γ、IL-10检测及临床意义 被引量:4

Determination of Serum TNF-α,IFN-γ,and IL-10 in Patients with Multiple Sclerosis and Their Clinical Significance
下载PDF
导出
摘要 目的探讨肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)、白细胞介素-10(IL-10)在多发性硬化(MS)免疫病理机制中的作用。方法采用ELISA法对42例MS患者(其中发作期25例,缓解期17例)和25名健康人(对照组)血清中TNF-α、IFN-γ、IL-10进行测定,并进行各组间分析。结果MS患者发作期TNF-α、IFN-γ水平比缓解期及对照组明显升高,IL-10水平比缓解期及对照组明显下降。结论TNF-α、IFN-γ可能与MS免疫病理过程有关,可作为评价MS活动性的辅助指标之一。IL-10对MS病情的缓解及稳定起重要作用,可作为MS缓解的指标。 Objective To investigate the pathogenic role of TNF-α IFN-γ, and IL-10 in multiple sclerosis. Methods Serum TNF-α, IFN-γ, and IL-10 were determined by ELISA in 42 patients with multiple sclerosis and 25 healthy subject. Among 42 patient, 25 were in acute attack stage and 17 in alleviative stage. Results The levels of TNF-α and IFN-γ in cases with acute attack stage of multiple sclerosis were higher than those with alleviative stage and in controls. The levels of IL-10 in cases with acute attack stage of multiple sclerosis were lower than those with alleviative stage and in controls. Conclusion Serum TNF-α and IFN-γ participate in immunopathologic process of MS, may be an useful auxiliary laboratory markers for estimating the status of multiple sclerosis. IL-10 may play an important role in alleviative stage and may be laboratory markers of alleviative stage MS.
出处 《实用临床医学(江西)》 CAS 2008年第3期10-11,共2页 Practical Clinical Medicine
关键词 多发性硬化 肿瘤坏死因子-Α 干扰素-Γ 白细胞介素-10 multiple sclerosis TNF-α TNF-γ TNF-10
  • 相关文献

参考文献11

  • 1Poser C M,Paty T W,scheinberg L,et al. New Diagnostic Criteria for Multiple Sclerosis:Guideline for Reseaeh Protoeol[J].Ann Neurol, 1983,13 : 227.
  • 2戴茹娟,王嗣欣.细胞因子与多发性硬化[J].国外医学(神经病学.神经外科学分册),1996,23(5):225-227. 被引量:2
  • 3Link J, Soderstrom M,Olsson T, et al. Increased Transforming Growth Factor-beta, Interleukin-4, and Infterferon-gamma in Multiple Sclerosis[J]. Ann Neurol, 1994,36(3) : 379-386.
  • 4Sharief M K. Association between Tumor Necrosis Factor-alpha and Disease Progression in Patients with Multiple Sclerosis [J]. N Engl J Med,1991,325(7) :467-472.
  • 5Glabinski A, Mirecxka M,Pokoca L. Tumor Necrosis Factor Alpha but Not Lymphotoxin is Overproduced by Blood Mononuclear Cells in Multiple Sclerosis[J]. Acta Neurol Scand, 1995,91(4) : 276-279.
  • 6Chung I Y, Norris J G, Benveniste E N. Differential Tumor Necrosis Factor Alpha Expression by Astrocytes from Experimental Allergic Encephalomyelitis-susceptible and Resistant Rat Strains[J]. J Exp Med,1991,173(4):801-811.
  • 7Benvenuto R, Paroli M, Buttinelli C. Tumour Necrosis Factor-alpha Synthesis by Cerebrospinal-fluid-derived T Cell Clones from Patients with Multiple Sclerosis[J]. Clin Exp Immunol, 1991,84(1) :97-102.
  • 8Porrini A M,Reder A T. IFN-gamma,IFN-beta,and PGE1 Affect Monokine Secretion:Relevance to Monocyte Activation in Multiple Sclerosis[J]. Cell Immunol,1994,157 (2):428-438.
  • 9杨德刚,胡长林.反映多发性硬化疾病活动性的免疫学指标[J].国外医学(神经病学.神经外科学分册),2003,30(6):539-541. 被引量:1
  • 10Makhlouf K, Weiner H L, Khoory S J. Increased Percentage of IL-12^+ Monocytes in the Blood Correlates with the Presence of Active MRI lesions in MS[J]. J Neuroimmunol,2001, 119(1) :145-149.

二级参考文献21

  • 1van Boxel-Dezaire AHH,Smits M,van Trigt-Hoff SCJ,et al.Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis.J Neuroimmunol,2001,120:152-160.
  • 2Makhlouf K,Weiner HL,Khoury SJ.Increased percentage of IL-12 +monocytes in the blood xorrelates with the presence of active MRI lesions in MS.J Neuroimmunol,2001,119:145-149.
  • 3Losy J,Michalowska-Wender G,Wender M,et al.Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone).Folia Neuropathol,2002,40(4):173-175.
  • 4van Boxel-Desaire AHH,Hoff SCJ,Van Oo sten BW,et al.Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterrize different didease stages inmultiple sclerosis.Ann Neurol,1999,45:695-703.
  • 5Wauubant E,Gee L,Bacchetti P,et al.Relationship between seum levels of IL-10.MRI acivity and interferon beta-1a therapy in patient with relapsing remitting MS.J Neuroimmunol,2001,112:139-145.
  • 6Rudick RA,Ransohoff RM,Lee JC,et al.In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis.Neurology,1998,50:1294-1300.
  • 7Liu Z,Pelfey CM,Cotleur A,et al.Immunomodultory effects of interferon beta-1a inmultiple sclerosis.J Neuroimmunol,2001,112:153-162.
  • 8Losy J,Niezgoda A.IL-18 in patients with multiple sclerosis.Acta Neurol Scand,2001,104(3):171-173.
  • 9Teleshova N,Bao W,Kivisakk P,et al.Elevated CD40 ligand expressing blood T-cell levels in multiple scleosis are reversed byinterferon-beta treatment.Scand J Immunol,2000,51:312-320.
  • 10Anderson DE,Sharpe AH,Hafler D.The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous sysyem.Curr Opin Immunol,1999,11:677-683.

共引文献1

同被引文献31

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部